FDA to review cell therapy rules with industry input, raising safety questions
H.R. 340 — The HCT/P Modernization Act of 2025 · Filed by Dan Crenshaw (R-TX) · 1 cosponsor · Introduced Jan 13, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the FDA to streamline oversight of human cell and tissue products (HCT/Ps)—including stem cells and cellular therapies—by publishing educational materials and best practices, conducting stakeholder workshops, establishing a public comment docket, and delivering a report to Congress by September 2026 with recommendations on modernizing HCT/P regulations. The bill does not change existing law; it mandates FDA transparency, stakeholder engagement, and a regulatory review focused on reducing burden while maintaining public health protections.
Why we flagged it
The bill's stated purpose is streamlining oversight, but its operative mechanism is a regulatory review explicitly tasked with considering 'regulatory burden' alongside public health. This frames the bill as deregulation-by-study, not mere transparency.
What the text implies
- The bill's focus on 'minimal manipulation' and 'homologous use' standards suggests the FDA may be pressured to relax definitions that currently restrict which cell/tissue products can be marketed with minimal oversight. Loosening these standards could allow more products to bypass full clinical trial requirements.
- The 'regulatory burden' language in the report mandate (section 4) signals an intent to reduce compliance costs for industry, not to strengthen protections. This may result in fewer inspections, lighter documentation requirements, or faster approval pathways.
- The bill does not mandate that the FDA's final recommendations prioritize public health over industry convenience. The report must 'take into account' burden, science, access, AND health—but assigns no hierarchy, leaving the FDA to balance competing interests without congressional guidance.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Citizens gain transparency and stakeholder input into HCT/P regulation, potentially accelerating access to cellular therapies. However, the bill's emphasis on reducing 'regulatory burden' and modernizing rules around 'minimal manipulation' and 'homologous use' may lower safety standards or accelerate approval of products with less rigorous evidence, creating a trade-off between access and protection.
Who stands to gain
- HCT/P manufacturers and tissue banks
- Cellular therapy developers and biotech firms
- Academic medical centers and research organizations offering HCT/P services
Named in the bill
FDA (Food and Drug Administration), HHS (Department of Health and Human Services), Tissue Reference Group, Food and Drug Omnibus Reform Act of 2022, Public Health Service Act (section 361), 21 CFR 1271.3 (HCT/P definitions), 21 CFR 1271.10 (HCT/P regulations)
Where it stands
1 cosponsor: 1 Democrats.
- Jan 13, 2025 — Introduced · Congress.gov: “Introduced in House”
- Jan 13, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (4,330 characters) on Aug 19, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“FDA to review cell therapy rules with industry input, raising safety questions” QuorumCivic. https://share.quorumcivic.app/bill/119/hr340 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.